The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

##STR00001##

In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.

Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first, the second, or the first and the second polypeptide comprise the mutation Y436A (numbering according to the EU index).

The present invention provides isolated proteins isolatable from a Pasteurella spp. such as P. multocida. Also provided by the present invention are compositions that include one or more of the proteins, and methods for making and methods for using the proteins.

The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.

The invention relates to heterodimeric proteins, and their methods of production and collection, that are useful to treat human disease.

Embodiments of the present disclosure relate to chimeric antibodies which specifically bind to Borrelia decorin-binding protein A (DbpA) antigens and compositions or kits comprising such antibodies. The disclosure further relates to use of such antibodies in the detection of Borrelia sp. in samples, e.g., biological samples such as human blood and/or tissues of deer, ticks and other carriers of Borrelia. Embodiments of the disclosure further relate to diagnosis and/or therapy of Lyme disease using the chimeric antibodies and/or compositions containing the chimeric antibodies.

Embodiments of the present disclosure relate to chimeric antibodies which specifically bind to Borrelia decorin-binding protein A (DbpA) antigens and compositions or kits comprising such antibodies. The disclosure further relates to use of such antibodies in the detection of Borrelia sp. in samples, e.g., biological samples such as human blood and/or tissues of deer, ticks and other carriers of Borrelia. Embodiments of the disclosure further relate to diagnosis and/or therapy of Lyme disease using the chimeric antibodies and/or compositions containing the chimeric antibodies.

The present invention relates to immunogenic immune complexes, related compositions, and related methods.